30 . 04 .2019
Press release
A Decade of Dysport®: Galderma Celebrates 10 Years Since FDA Approval of Dysport in the U.S.
08 . 04 .2019
Press release
Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease
06 . 04 .2019
Press release
Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines
08 . 03 .2019
Press release
Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session
01 . 03 .2019
Press release
Galderma: New data reveals benefits of combining oral and topical treatment in patients with severe papulopustular rosacea
01 . 03 .2019
Press release
Galderma Announces Publication of Pivotal Phase 3 PERFECT 1 and PERFECT 2 Clinical Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne in the Journal of the American Academy of Dermatology
23 . 01 .2019
Press release
Galderma Announces Formation of Women in Aesthetics Leadership Council